Tumor-specific positron emission tomography imaging in patients: [ 18F] fluorodeoxyglucose and beyond

Clinical Cancer Research

Volumn 13, Issue 12, 2007, Pages 3460-3469

  Mankoff, David A ^a,b   Eary, Janet F ^a   Link, Jeanne M ^a   Muzi, Mark ^a   Rajendran, Joseph G ^a   Spence, Alexander M ^a   Krohn, Kenneth A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB;

CANCER DIAGNOSIS; CANCER PATIENT; GASTROINTESTINAL TUMOR; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

ANIMALS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 34250712408     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0074     Document Type: Review

References (123)

1. Blasburg R. Imaging update: new windows, new views. Clin Cancer Res 2007;13:3444-8.
2. Jackson A, O'Connor J, Parker G, Jayson G. Imaging tumor vascular heterogeneity and angiogenesis using DCE-MRI. Clin Cancer Res 2007;13:3449-59.
3. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785-808.
4. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005;11: 7967-85.
5. Wester HJ. Nuclear imaging probes: from bench to bedside. Clin Cancer Res 2007;13:3476-81.
6. Mankoff DA, Krohn KA. PET imaging of response and resistance to cancer therapy. In: Teicher B, editor. Drug resistance in cancer. Totowa (NJ): Humana Press; 2006. p.105- 22.
7. Eubank WB, Mankoff DA, Schmiedl UP, et al. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy. AJR Am J Roentgenol 1998;171:1103-10.
8. Vansteenkiste JF. PET scan in the staging of non-small cell lung cancer. Lung Cancer 2003;42 Suppl 1: S27-37.
9. Alessio AM, Kinahan PE, Cheng PM, Vesselle H, Karp JS. PET/CT scanner instrumentation, challenges, and solutions. Radiol Clin North Am 2004; 42:1017-32, vii.
10. Husband JE. Monitoring tumor response. Eur Radiol 1996;6:775-85.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al.; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
12. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692-8.
13. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464-71.
14. 18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-95.
15. Shields AF, Mankoff DA, Link JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998;39:1757-62.
16. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18: 1676-88.
17. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-11.
18. Nasr A, Stulberg J, Weitzman S, Gerstle JT. Assessment of residual posttreatment masses in Hodgkin's disease and the need for biopsy in children. J Pediatr Surg 2006;41:972-4.
19. 18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000;27:731-43.
20. 18F]-2- fluoro-2-deoxy-D-glucose and positron-emission tomography. J Clin Pharmacol 2001;41: Suppl:104-6S.
21. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003;21: 1285-92.
22. Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44:1806-14.
23. Spence AM, Muzi M, Graham MM, et al. 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. Clin Cancer Res 2002;8: 971-9.
24. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21:2651-7.
25. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006;24:3282-92.
26. Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E. Cancer biomarkers: a systems approach. Nat Biotechnol 2006;24:905-8.
27. 18F]fluoro-2-deoxy-D-glucose- positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498-505.
28. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006;24: 2793-9.
29. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19:2797-803.
30. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
31. 18F)2-fluoro-2-deoxy- D-glucose: validation of method. Ann Neurol 1979;6:371.
32. 18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 1979;44: 127-37.
33. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 2005;32: 663-71.
34. Huang S-C. Anatomy of SUV. Nucl Med Biol 2000; 27:643-6.
35. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47: 1059-66.
36. D-glucose: variations with body weight and a method for correction. Radiology 1993;189: 847-50.
37. Warburg O. The metabolism of tumors. New York: Richard R. Smith; 1931.
38. Spence AM, Graham MM, Muzi M, et al. Feasibility of imaging pentose cycle glucose metabolism in gliomas with PET: studies in rat brain tumor models. J Nucl Med 1997;38:617-24.
39. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625-32.
40. Mathapala S, Rempel A, Pederson P. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 1997;29: 339-43.
41. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
42. Linden HM, Krohn KA, Livingston RB, Mankoff DA. Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response? Clin Cancer Res 2006;12:5608-10.
43. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47.
44. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004;22:4217-26.
45. Brand K. Aerobic glycolysis by proliferating cells: protection against oxidative stress at the expense of energy yield. J Bioenerg Biomembr 1997;29: 335-64.
46. Spence AM, Muzi M, Graham MM, et al. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose, and FDG: analysis of the FDG lumped constant. J Nucl Med 1998;39:440-8.
47. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A31 and T47D cells in culture. Cancer Res 1999;59: 4709-171.
48. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 2004;45: 1829-37.
49. Eubank W, Mankoff D. Current and future uses of PET in breast cancer imaging. Semin Nucl Med 2004;34:224-40.
50. Macapinlac HA. FDG PET and PET/CT imaging in lymphoma and melanoma. Cancer J 2004;10: 262-70.
51. Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrun A. Positron emission tomography in urological oncology. J Urol 1998;159: 347-56.
52. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792-7.
53. 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16.
54. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-87.
55. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29:1149-54.
56. 18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107-13.
57. Morris MJ, Akhurst T, Osman I, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59:913-8.
58. 18F]- fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 2001;11:1169-75.
59. Mankoff D, Bellon J. PET imaging of cancer: FDG and beyond. Semin Radiat Oncol 2001;11:16-27.
60. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231:305-32.
61. 18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989;15:61-6.
62. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-80.
63. 18F]-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004;45:17-21.
64. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39:2012-20.
65. Van den Abbeele AD, Group ftGCPS. [F-18]-FDG in PET provides early evidence of biological response to ST1571 in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol 2001;20:362a.
66. Su H, Bodenstein C, Dumont RA, et al. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2006;12:5659-67.
67. Hicks RJ. The role of PET in monitoring therapy. Cancer Imaging 2005;5:51-7.
68. 18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy. J Clin Oncol 2006;24:3026-31.
69. 18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005;23:8828-34.
70. Specht JM, Tam SL, Kurland BF, et al. Serial 2-[(18)F] fluoro-2-deoxy-D: -glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat. Epub 2007 Feb 10.
71. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-8.
72. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500-9.
73. 18F]-D-glucose. Cancer 1998;82:2227-34.
74. Patronas NJ, Di Chiro G, Kufta C, et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1985;62:816-22.
75. 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 2002;43:1667-73.
76. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004;5:531-40.
77. Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995;71:146-9.
78. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005;43: 169-87.
79. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098-104.
80. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206.
81. Hockenbery D. Defining apoptosis. Am J Pathol 1995;146:16-9.
82. Krohn KA, Mankoff DA, Eary JF. Imaging cellular proliferation as a measure of response to therapy. J Clin Pharmacol 2001;41:96-103S.
83. Kaklamani V, O'Regan RM. New targeted therapies in breast cancer. Semin Oncol 2004;31:20-5.
84. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: a comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995;36:1766-74.
85. 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004;45:366-73.
86. Gonzalez Trotter DE, Manjeshwar RM, Doss M, et al. Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner. J Nucl Med 2004;45:1237-44.
87. Wilson CBJH, Lammertsma AA, McKenzie CG, Sikora K, Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and non-invasive dynamic method. Cancer Res 1992;52:1592-7.
88. Zasadny KR, Tatsumi M, Wahl RL. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 2003;30:274-80.
89. 3 expression in man. Clin Cancer Res 2006;12:3942-9.
90. 3-targeted imaging of lung cancer. Neoplasia 2005;7: 271-9.
91. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326-36.
92. 11C]methyl-halo-CGS2 7023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol 2002;29:761-70.
93. Berger F, Gambhir SS. Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer. Breast Cancer Res 2001;3: 28-35.
94. Sledge GJ, McGuire W. Steroid hormone receptors in human breast cancer. Adv Cancer Res 1983;38: 61-75.
95. Katzenellenbogen JA, Welch MJ, Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res 1997;17:1573-6.
96. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988;169:45-8.
97. 18F] fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 2001;42:679-84.
98. Aboagye EO, Price PM. Use of positron emission tomography in anticancer drug development. Invest New Drugs 2003;21:169-81.
99. Sutherland R. Tumor hypoxia and gene expression. Acta Oncol 1998;37:567-74.
100. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-52.
101. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003; 55:1233-8.
102. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006;12:5435-41.
103. Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging 2006;33 Suppl 13:44-53.
104. Kaye SB. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 1998;10 Suppl 1:S15-9.
105. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53: 977-84.
106. Ciarmiello A, Vecchio SD, Silvestro P, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998;16: 1677-83.
107. Mankoff DA, Dunnwald LK, Gralow JR, et al. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nucl Med Biol 2002;29:719-27.
108. Hendrikse NH, de Vries EG, Eriks-Fluks L, et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 1999;59:2411-6.
109. Sasongko L, Link JM, Muzi M, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 2005;77:503-14.
110. 18F-paclitaxel in nonhuman primates. J Nucl Med 2003;44:1330-9.
111. Cleaver JE. Thymidine metabolism and cell kinetics. Frontiers Biol 1967;6:43-100.
112. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am 2005; 43:153-67.
113. Grierson JR, Shileds AF. Radiosymthesis of 3′-deoxy-3′-[F-18] -fluorothymidine: [F-18]-FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000;27:143-56.
114. Pio BS, Park CK, Satyamurthy N, Czernin J, Phelps ME, Silverman DH. PET with fluoro-L-thymidine allows early prediction of breast cancer response to chemotherapy. J Nucl Med 2003;44:76P.
115. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med 2005;46:371-80.
116. 18F-fluorothymidine in patients with gliomas. J Nucl Med 2006;47:1612-21.
117. 11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. Mol Imaging 2002;1:145-50.
118. Blankenberg F, Katsikis P, Tait J, et al. Imaging of apoptosis (programmed cell death) with 99mTc Annexin V. J Nucl Med 1999;40:184-91.
119. van de Wiele C, Lahorte C, Vermeersch H, et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC Annexin V single photon emission computed tomography. J Clin Oncol 2003;21: 3483-7.
120. Mandl SJ, Mari C, Edinger M, et al. Multi-modality imaging identifies key times for Annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging 2004;3:1-8.
121. Collingridge DR, Glaser M, Osman S, et al. In vitro selectivity, in vivo biodistribution, and tumour uptake of Annexin V radiolabelled with a positron emitting radioisotope. Br J Cancer 2003;89:1327-33.
122. 18F-Annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005;46:658-66.
123. Lahorte CM, Vanderheyden JL, Steinmetz N, Van de Wiele C, Dierckx RA, Slegers G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 2004;31: 887-919.